News

With the investment, Pioneer has completed $2.5m investment of total $5.5m. The investment forms part of the expansion of the NeutroPhase distribution agreement for Southeast Asia signed on

Bio Rad clinical diagnostics group president John Goetz said the agreement provides Premier members with access to the company’s traditional product lines and automated platforms of cost-effective blood

Revenue for third quarter of 2012 was $5.76m compared to $5.01m for the third quarter of 2011. The company reported a net loss of $20.47m, or $0.16 per

The organisation has shared the Outstanding Achievement award along with its project partners GEA, Siemens, Sagentia and the Universities of Newcastle, Warwick and Surrey The company has also

The technology will enable CCS to provide its customers with transfected non-tumor origin cell lines including CAP-TTM cells, designed for use in cell based assays and protein production

The study has met its primary endpoint of superiority in HbA1c reduction versus placebo and the decrease in FPG was also statistically significant. The 12 week phase II

The companies are also planning to use the new markers for future companion test commercialization associated with masitinib, a molecule developed by AB science to treat pancreatic cancer.

The placebo-controlled, parallel-arm study demonstrated nearly 50% reduction in the change of total kidney volume among autosomal dominant polycystic kidney disease (ADPKD) patients as compared to placebo over

In addition, the committee also favoured the risk-benefit profile of raxibacumab. The raxibacumab anti-toxin development programme has been designed to get approval under the regulatory pathway using animal